Park Avenue Securities trims Novartis stake by 8.2% amid mixed analyst ratings and recent dividend payout.

Park Avenue Securities LLC reduced its holdings in Novartis AG by 8.2% in Q4, selling 4,313 shares and holding 48,579 shares valued at about $6.7 million. Despite this, other institutional investors like Lockheed Martin and Vanguard increased their stakes. Novartis recently announced a $2 billion acquisition to boost its oncology pipeline and declared a substantial dividend payout of $4.773 per share. Analyst opinions are mixed, with ratings ranging from hold to strong buy, reflecting cautious optimism about the company's future prospects amid regulatory and market challenges.